Merck & Co. might consider settling a small number of Vioxx cases involving people who claim they were harmed by the painkiller and who fit a very narrow profile, The Wall Street Journal reported on Friday.
The company’s general counsel stressed that Merck had not changed its strategy of fighting every case in court, it said.
